{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:57:12Z","timestamp":1771667832838,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1C1C1003735"],"award-info":[{"award-number":["2021R1C1C1003735"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dipeptidyl peptidase-4 inhibitors (DPP4is) and sodium glucose cotransporter-2 inhibitors (SGLT2is) have been speculated to have a potential to increase infection risks in type 2 diabetes mellitus (T2DM) patients. We performed a cohort study using the Korean health insurance data to investigate infection risks with each drug class relative to metformin in insulin-treated T2DM patients. After propensity score matching, we included 1,498 and 749 patients in DPP4i\u2009+\u2009insulin vs metformin\u2009+\u2009insulin and 300 and 549 patients in SGLT2i\u2009+\u2009insulin vs metformin\u2009+\u2009insulin, respectively. In stratified analyses per patient factor, none of the odds ratios (ORs) were associated with a statistical significance across respiratory, genital, and urinary tract infections (UTIs), except that of the male stratum for respiratory infections (OR 0.77, p\u2009=\u20090.04). With regard to SGLT2is, a higher risk of genital infections was analyzed with their use than with metformin therapy (OR 1.76, p\u2009=\u20090.03). In stratified analyses, the OR for genital infections remained significant in the baseline cardiovascular disease stratum (OR 2.29, p\u2009=\u20090.01). No increased UTI risk was detected with SGLT2is compared against metformin. In this study on insulin-receiving T2DM patients, DPP4is were not associated with increased infection risks, whereas SGLT2is led to a higher risk for genital infections, but not for UTIs, relative to metformin.<\/jats:p>","DOI":"10.1038\/s41598-023-45793-x","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:02:08Z","timestamp":1698433328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients"],"prefix":"10.1038","volume":"13","author":[{"given":"Sanghwa","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiseon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunna","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooyoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"45793_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad, E., Lim, S., Lamptey, R., Webb, D. R. & Davies, M. J. Type 2 diabetes. Lancet 400, 1803\u20131820. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5 (2022).","journal-title":"Lancet"},{"key":"45793_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic, D., Shaw, J. E. & Magliano, D. J. The burden and risks of emerging complications of diabetes mellitus. Nat. Rev. Endocrinol. 18, 525\u2013539. https:\/\/doi.org\/10.1038\/s41574-022-00690-7 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"45793_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/TCRM.S169964","volume":"14","author":"Y Noh","year":"2018","unstructured":"Noh, Y., Lee, S. & Shin, S. Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients. Ther. Clin. Risk Manag. 14, 1563\u20131571. https:\/\/doi.org\/10.2147\/TCRM.S169964 (2018).","journal-title":"Ther. Clin. Risk Manag."},{"key":"45793_CR4","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/ijc.31870","volume":"144","author":"Y Noh","year":"2019","unstructured":"Noh, Y., Jeon, S. M. & Shin, S. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. Int. J. Cancer 144, 1530\u20131539. https:\/\/doi.org\/10.1002\/ijc.31870 (2019).","journal-title":"Int. J. Cancer"},{"key":"45793_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/dom.14142","volume":"22","author":"ML Morieri","year":"2020","unstructured":"Morieri, M. L. et al. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis. Diabetes Obes. Metab. 22, 1925\u20131934. https:\/\/doi.org\/10.1111\/dom.14142 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/dom.14353","volume":"23","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi, Y. et al. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database. Diabetes Obes. Metab. 23, 1379\u20131388. https:\/\/doi.org\/10.1111\/dom.14353 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.910","volume":"10","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacol. Res. Perspect. 10, e00910. https:\/\/doi.org\/10.1002\/prp2.910 (2022).","journal-title":"Pharmacol. Res. Perspect."},{"key":"45793_CR8","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/pds.4262","volume":"26","author":"Y Noh","year":"2017","unstructured":"Noh, Y. et al. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. Pharmacoepidemiol. Drug Saf. 26, 1338\u20131346. https:\/\/doi.org\/10.1002\/pds.4262 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"45793_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/dc17-2131","volume":"41","author":"IM Carey","year":"2018","unstructured":"Carey, I. M. et al. Risk of infection in type 1 and type 2 diabetes compared with the general population: A matched cohort study. Diabetes Care 41, 513\u2013521. https:\/\/doi.org\/10.2337\/dc17-2131 (2018).","journal-title":"Diabetes Care"},{"key":"45793_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12879-018-2975-2","volume":"18","author":"W Abu-Ashour","year":"2018","unstructured":"Abu-Ashour, W., Twells, L. K., Valcour, J. E. & Gamble, J. M. Diabetes and the occurrence of infection in primary care: A matched cohort study. BMC Infect. Dis. 18, 67. https:\/\/doi.org\/10.1186\/s12879-018-2975-2 (2018).","journal-title":"BMC Infect. Dis."},{"key":"45793_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1573399815666191024085838","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16, 442\u2013449. https:\/\/doi.org\/10.2174\/1573399815666191024085838 (2020).","journal-title":"Curr. Diabetes Rev."},{"issue":"2753\u20132786","key":"45793_CR12","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(2753\u20132786), 2022. https:\/\/doi.org\/10.2337\/dci22-0034 (2022).","journal-title":"Diabetes Care"},{"key":"45793_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4093\/dmj.2021.0156","volume":"45","author":"KY Hur","year":"2021","unstructured":"Hur, K. Y. et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean diabetes association. Diabetes Metab. J. 45, 461\u2013481. https:\/\/doi.org\/10.4093\/dmj.2021.0156 (2021).","journal-title":"Diabetes Metab. J."},{"key":"45793_CR14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard, K. R., Shelburne, J. S. & Kirk, J. K. Tolerability of dipeptidyl peptidase-4 inhibitors: A review. Clin. Ther. 33, 1609\u20131629. https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.028 (2011).","journal-title":"Clin. Ther."},{"key":"45793_CR15","doi-asserted-by":"publisher","unstructured":"Wang, F., He, Y., Zhang, R., Zeng, Q. & Zhao, X. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore) 96, e7638. https:\/\/doi.org\/10.1097\/MD.0000000000007638 (2017).","DOI":"10.1097\/MD.0000000000007638"},{"key":"45793_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s13300-018-0488-z","volume":"9","author":"F Gomez-Peralta","year":"2018","unstructured":"Gomez-Peralta, F., Abreu, C., Gomez-Rodriguez, S., Barranco, R. J. & Umpierrez, G. E. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios. Diabetes Ther. 9, 1775\u20131789. https:\/\/doi.org\/10.1007\/s13300-018-0488-z (2018).","journal-title":"Diabetes Ther."},{"key":"45793_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2147\/DMSO.S202024","volume":"12","author":"N Wang","year":"2019","unstructured":"Wang, N., Yang, T., Li, J. & Zhang, X. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Metab. Syndr. Obes. 12, 1513\u20131526. https:\/\/doi.org\/10.2147\/DMSO.S202024 (2019).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"45793_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153\u2013165. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004 (2006).","journal-title":"Cell Metab."},{"key":"45793_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","volume":"55","author":"GP Fadini","year":"2011","unstructured":"Fadini, G. P. & Avogaro, A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul. Pharmacol. 55, 10\u201316. https:\/\/doi.org\/10.1016\/j.vph.2011.05.001 (2011).","journal-title":"Vascul. Pharmacol."},{"key":"45793_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"Amori, R. E., Lau, J. & Pittas, A. G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298, 194\u2013206. https:\/\/doi.org\/10.1001\/jama.298.2.194 (2007).","journal-title":"JAMA"},{"key":"45793_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/dc10-1771","volume":"34","author":"MJ Willemen","year":"2011","unstructured":"Willemen, M. J. et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 34, 369\u2013374. https:\/\/doi.org\/10.2337\/dc10-1771 (2011).","journal-title":"Diabetes Care"},{"key":"45793_CR22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/DDDT.S50773","volume":"8","author":"MA Nauck","year":"2014","unstructured":"Nauck, M. A. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Dev. Ther. 8, 1335\u20131380. https:\/\/doi.org\/10.2147\/DDDT.S50773 (2014).","journal-title":"Drug Des. Dev. Ther."},{"key":"45793_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","volume":"104","author":"FM Hasan","year":"2014","unstructured":"Hasan, F. M., Alsahli, M. & Gerich, J. E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 104, 297\u2013322. https:\/\/doi.org\/10.1016\/j.diabres.2014.02.014 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"45793_CR24","unstructured":"FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about serious urinary tract infections. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious (2015)."},{"key":"45793_CR25","unstructured":"FDA. FDA warns about rare occurrences of a serious infections of the genital area with SGLT2 inhibitors for diabetes. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes (2018)."},{"key":"45793_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577","volume":"9","author":"JR Donnan","year":"2019","unstructured":"Donnan, J. R. et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open 9, e022577. https:\/\/doi.org\/10.1136\/bmjopen-2018-022577 (2019).","journal-title":"BMJ Open"},{"key":"45793_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin, R. et al. SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55, 503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0 (2018).","journal-title":"Acta Diabetol."},{"key":"45793_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.diabres.2017.06.018","volume":"130","author":"S Gadzhanova","year":"2017","unstructured":"Gadzhanova, S., Pratt, N. & Roughead, E. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res. Clin. Pract. 130, 180\u2013185. https:\/\/doi.org\/10.1016\/j.diabres.2017.06.018 (2017).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"45793_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda, P. et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study. BMJ 363, k4365. https:\/\/doi.org\/10.1136\/bmj.k4365 (2018).","journal-title":"BMJ"},{"key":"45793_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave, C. V. et al. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. Ann. Intern. Med. 171, 248\u2013256. https:\/\/doi.org\/10.7326\/M18-3136 (2019).","journal-title":"Ann. Intern. Med."},{"key":"45793_CR31","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/dom.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"Lega, I. C. et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes. Metab. 21, 2394\u20132404. https:\/\/doi.org\/10.1111\/dom.13820 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR32","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu, J. et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci. Rep. 7, 2824. https:\/\/doi.org\/10.1038\/s41598-017-02733-w (2017).","journal-title":"Sci. Rep."},{"key":"45793_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.numecd.2017.12.007","volume":"28","author":"G Zoppini","year":"2018","unstructured":"Zoppini, G. et al. Mortality from infectious diseases in diabetes. Nutr. Metab. Cardiovasc. Dis. 28, 444\u2013450. https:\/\/doi.org\/10.1016\/j.numecd.2017.12.007 (2018).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"45793_CR34","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/dom.14132","volume":"22","author":"B Zhang","year":"2020","unstructured":"Zhang, B., Liu, S., Zhang, L., Dong, Y. & Zhang, S. Admission fasting blood glucose predicts 30-day poor outcome in patients hospitalized for COVID-19 pneumonia. Diabetes Obes. Metab. 22, 1955\u20131957. https:\/\/doi.org\/10.1111\/dom.14132 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijid.2020.01.017","volume":"92","author":"Q Zou","year":"2020","unstructured":"Zou, Q. et al. Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments. Int. J. Infect. Dis. 92, 208\u2013213. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.017 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"45793_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s15010-015-0801-y","volume":"43","author":"A Vila-Corcoles","year":"2015","unstructured":"Vila-Corcoles, A. et al. Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection 43, 699\u2013706. https:\/\/doi.org\/10.1007\/s15010-015-0801-y (2015).","journal-title":"Infection"},{"key":"45793_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.amjms.2016.02.032","volume":"352","author":"MS Bader","year":"2016","unstructured":"Bader, M. S. et al. Community-acquired pneumonia in patients with diabetes mellitus: Predictors of complications and length of hospital stay. Am. J. Med. Sci. 352, 30\u201335. https:\/\/doi.org\/10.1016\/j.amjms.2016.02.032 (2016).","journal-title":"Am. J. Med. Sci."},{"key":"45793_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/dom.14086","volume":"22","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Diabetes Obes. Metab. 22, 1443\u20131454. https:\/\/doi.org\/10.1111\/dom.14086 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR39","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/dom.14105","volume":"22","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. Diabetes Obes. Metab. 22, 1907\u20131914. https:\/\/doi.org\/10.1111\/dom.14105 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR40","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40618-020-01236-2","volume":"43","author":"GP Fadini","year":"2020","unstructured":"Fadini, G. P., Morieri, M. L., Longato, E. & Avogaro, A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J. Endocrinol. Invest. 43, 867\u2013869. https:\/\/doi.org\/10.1007\/s40618-020-01236-2 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"45793_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/dom.14099","volume":"22","author":"H Li","year":"2020","unstructured":"Li, H. et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes. Metab. 22, 1897\u20131906. https:\/\/doi.org\/10.1111\/dom.14099 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR42","doi-asserted-by":"publisher","unstructured":"Wvan der Zanden, R. et al. Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: A population-based cohort study. PLoS One 10, e0139367. https:\/\/doi.org\/10.1371\/journal.pone.0139367 (2015).","DOI":"10.1371\/journal.pone.0139367"},{"key":"45793_CR43","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1111\/bcp.13288","volume":"83","author":"J Gorricho","year":"2017","unstructured":"Gorricho, J. et al. Use of oral antidiabetic agents and risk of community-acquired pneumonia: A nested case-control study. Br. J. Clin. Pharmacol. 83, 2034\u20132044. https:\/\/doi.org\/10.1111\/bcp.13288 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"45793_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1369","volume":"344","author":"T Karagiannis","year":"2012","unstructured":"Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R. & Tsapas, A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ 344, e1369. https:\/\/doi.org\/10.1136\/bmj.e1369 (2012).","journal-title":"BMJ"},{"key":"45793_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/dom.14097","volume":"22","author":"GP Fadini","year":"2020","unstructured":"Fadini, G. P. et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes. Metab. 22, 1946\u20131950. https:\/\/doi.org\/10.1111\/dom.14097 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.diabet.2020.05.008","volume":"46","author":"AJ Scheen","year":"2020","unstructured":"Scheen, A. J., Marre, M. & Thivolet, C. Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. Diabetes Metab. 46, 265\u2013271. https:\/\/doi.org\/10.1016\/j.diabet.2020.05.008 (2020).","journal-title":"Diabetes Metab."},{"key":"45793_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/03007995.2020.1729710","volume":"36","author":"T Kameda","year":"2020","unstructured":"Kameda, T., Kumamaru, H., Nishimura, S., Kohsaka, S. & Miyata, H. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: Dosing pattern for metformin initiators. Curr. Med. Res. Opin. 36, 749\u2013756. https:\/\/doi.org\/10.1080\/03007995.2020.1729710 (2020).","journal-title":"Curr. Med. Res. Opin."},{"key":"45793_CR48","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou, D. et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med. 159, 262\u2013274. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007 (2013).","journal-title":"Ann. Intern. Med."},{"key":"45793_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave, C. V., Schneeweiss, S. & Patorno, E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes. Metab. 21, 434\u2013438. https:\/\/doi.org\/10.1111\/dom.13531 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"45793_CR50","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s13300-018-0452-y","volume":"9","author":"GP Fadini","year":"2018","unstructured":"Fadini, G. P. et al. Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study. Diabetes Ther. 9, 1477\u20131490. https:\/\/doi.org\/10.1007\/s13300-018-0452-y (2018).","journal-title":"Diabetes Ther."},{"key":"45793_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.diabres.2017.11.023","volume":"136","author":"M d'Emden","year":"2018","unstructured":"d\u2019Emden, M., Amerena, J., Deed, G., Pollock, C. & Cooper, M. E. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 136, 23\u201331. https:\/\/doi.org\/10.1016\/j.diabres.2017.11.023 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"45793_CR52","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84353","volume":"17","author":"S Rabizadeh","year":"2019","unstructured":"Rabizadeh, S., Nakhjavani, M. & Esteghamati, A. Cardiovascular and renal benefits of SGLT2 inhibitors: A narrative review. Int. J. Endocrinol. Metab. 17, e84353. https:\/\/doi.org\/10.5812\/ijem.84353 (2019).","journal-title":"Int. J. Endocrinol. Metab."},{"key":"45793_CR53","first-page":"S5","volume":"66","author":"EM Miller","year":"2017","unstructured":"Miller, E. M. Elements for success in managing type 2 diabetes with SGLT-2 inhibitors: Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus. J. Fam. Pract. 66, S5\u2013S12 (2017).","journal-title":"J. Fam. Pract."},{"key":"45793_CR54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"AA Tahrani","year":"2013","unstructured":"Tahrani, A. A., Barnett, A. H. & Bailey, C. J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 1, 140\u2013151. https:\/\/doi.org\/10.1016\/S2213-8587(13)70050-0 (2013).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45793-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:03:21Z","timestamp":1698433401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45793"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45793-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"13 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18462"}}